Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

08-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

print
PRINT
insite
SEARCH

Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read more about KEYNOTE-021 here

print
PRINT

Related content

08-08-2017 | Non-small-cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials

19-04-2018 | Non-small-cell lung cancer | News

First-line pembrolizumab plus chemotherapy boosts advanced NSCLC outcomes
Image Credits